Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information (Details)

v3.25.2
Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
May 31, 2025
May 31, 2024
Operating expenses:    
Operating gain (loss) $ 9,661 $ (18,058)
Interest income 565 217
Interest on convertible notes (4,424) (4,659)
Amortization of discount on convertible notes (407) (1,076)
Amortization of debt issuance costs   (572)
Issuance costs for private placement of shares and warrants through placement agent   (2,819)
Loss on induced conversion (1,180) (6,680)
Finance charges (25) (2,584)
Loss on note extinguishment   (13,374)
Gain on restructuring of payables 407  
Loss on derivatives (852) (236)
Provision (benefit) for income taxes 0 0
Net income (loss) 3,745 (49,841)
Share based compensation recognized in general and administrative expense 800 2,400
Share based compensation recognized in research and development expense 800 0
Single reporting segment | Operating segment    
Operating expenses:    
General and administrative expense 6,434 8,403
Research and development 7,278 7,240
Return of clinical expenses (24,985)  
Stock-based compensation expense 1,612 2,415
Operating gain (loss) 9,661 (18,058)
Interest income 565 217
Interest on convertible notes (4,424) (4,659)
Amortization of discount on convertible notes (407) (1,076)
Amortization of debt issuance costs   (572)
Issuance costs for private placement of shares and warrants through placement agent   (2,819)
Loss on induced conversion (1,180) (6,680)
Finance charges (25) (2,584)
Loss on note extinguishment   (13,374)
Gain on restructuring of payables 407  
Loss on derivatives (852) (236)
Net income (loss) $ 3,745 $ (49,841)